secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2022-08-31T23:59:59+00:00
Accession:  0001370053-22-000049
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted
--------------------------------------------------------------------------------

- Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.
- No imsidolimab-related serious/severe AEs; safety profile acceptable across arms.
- Company discontinues imsidolimab development in HS; GEMINI-1 Phase 3 for GPP continues with data expected Q4 2023.
- Plans to outlicense imsidolimab prior to potential FDA approval for GPP; focus on rosnilimab and ANB032 immune cell modulators.
- Cash over $570M at Q2 end; AZURE Phase 2 rosnilimab data in alopecia areata anticipated Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/0001370053-22-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/anab-20220831.htm
  HTML page:      https://secwatch.observer/filing/0001370053-22-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer